Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic- and pre-psychotic symptoms

References

• Regier DA, Farmer ME, Rae DS, . Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990; 264: 2511–2518.
   PubMed Web of Science ®Google Scholar
• Compton MT, Furman AC, Kaslow NJ. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res 2004; 71:61–64.
   PubMed Web of Science ®Google Scholar
• Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005; 187: 306–313.
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184:110–117.
   PubMed Web of Science ®Google Scholar
• Moore TH, Zammit S, Lingford-Hughes A, . Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370:319–328.
   PubMed Web of Science ®Google Scholar
• Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry 2000; 34:468–475.
   PubMed Web of Science ®Google Scholar
• Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999; 249:45–49.
   PubMed Web of Science ®Google Scholar
• Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51:273–279.
   PubMed Web of Science ®Google Scholar
• Dervaux A, Laqueille X, Bourdel MC, . [Cannabis and schizophrenia: demographic and clinical correlates] [Usage du cannabis chez les patients presentant un premier episode psychotique et les sujets etres haut risque de la psychose: impact sur les psychotiques et pre-symptômes psychotiques]. Encephale 2003; 29:11–17.
   PubMed Web of Science ®Google Scholar
• Scheller-Gilkey G, Thomas SM, Woolwine BJ, Miller AH. Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophr Bull 2002; 28:223–231.
   PubMed Web of Science ®Google Scholar
• Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 2002; 252:86–92.
   PubMed Web of Science ®Google Scholar
• Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD. Cannabis use is not associated with the development of psychosis in an ‘ultra’ high-risk group. Aust N Z J Psychiatry 2002; 36: 800–806.
   PubMed Web of Science ®Google Scholar
• Yung AR, Phillips LJ, Yuen HP, . Psychosis prediction: 12-month follow up of a high-risk (‘prodromal’) group. Schizophr Res 2003; 60:21–32.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 2007; 151:151–154.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–176.
   PubMed Web of Science ®Google Scholar
• Miller TJ, McGlashan TH, Rosen JL, . Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002; 159:863–865.
   PubMed Web of Science ®Google Scholar
• Mueser KT, Yarnold PR, Levinson DF, . Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull 1990; 16:31–56.
   PubMed Web of Science ®Google Scholar
• Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2:1483–1486.
   PubMed Web of Science ®Google Scholar
• Zammit S, Moore TH, Lingford-Hughes A, . Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008; 193:357–363.
   PubMed Web of Science ®Google Scholar
• Smith MJ, Thirthalli J, Abdallah AB, Murray RM, Cottler LB. Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr Psychiatry 2009; 50:245–250.
   PubMed Web of Science ®Google Scholar
• Thirthalli J, Benegal V. Psychosis among substance users. Curr Opin Psychiatry 2006; 19:239–245.
   PubMed Web of Science ®Google Scholar
• Dixon L, Haas G, Weiden P, Sweeney J, Frances A. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients’ self-reports. Schizophr Bull 1990; 16:69–79.
   PubMed Web of Science ®Google Scholar
• Buckley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 1994; 151:385–389.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Amador XF, Flaum M, . The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res 1996; 20:69–77.
   PubMed Web of Science ®Google Scholar
• Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 1992; 85:127–130.
   PubMed Web of Science ®Google Scholar